GlobeNewswire: Aptose Biosciences, Inc. Contains the last 10 of 255 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:28:39ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/26/2852721/0/en/Aptose-Reports-Results-for-the-Fourth-Quarter-and-Full-Year-2023.html?f=22&fvtc=4&fvtv=26345Aptose Reports Results for the Fourth Quarter and Full Year 20232024-03-26T20:01:00Z<![CDATA[SAN DIEGO and TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months and year ended December 31, 2023, and provided a corporate update.]]>https://www.globenewswire.com/news-release/2024/03/18/2848185/0/en/Aptose-to-Report-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Provide-Corporate-Update-on-Tuesday-March-26-2024.html?f=22&fvtc=4&fvtv=26345Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 20242024-03-18T20:30:00Z<![CDATA[SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update.]]>https://www.globenewswire.com/news-release/2024/01/31/2821542/0/en/Aptose-Announces-Closing-of-9-7-Million-Public-Offering-and-Concurrent-4-Million-Private-Placement-with-Hanmi-Pharmaceutical-Including-Full-Exercise-of-Over-Allotment-Option.html?f=22&fvtc=4&fvtv=26345Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option2024-01-31T21:01:00Z<![CDATA[SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the closing of the previously announced public offering (the “Public Offering”) of 5,649,122 common shares of the Company (the “Common Shares”) and warrants at a combined offering price of US $1.71 per share. This includes 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option. Each Common Share was sold with a warrant to purchase a Common Share (a “Warrant Share”) at an exercise price of US $1.71 per Warrant Share.]]>https://www.globenewswire.com/news-release/2024/01/26/2817923/0/en/Aptose-Announces-Pricing-of-8-4-Million-Public-Offering-and-a-Concurrent-4-Million-Private-Placement-with-Hanmi-Pharmaceutical.html?f=22&fvtc=4&fvtv=26345Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical2024-01-26T13:00:01Z<![CDATA[SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the pricing of an underwritten public offering (the “Public Offering”) of 4,912,280 common shares of the Company (the “Common Shares”) at a public offering price of US $1.71 per share. Each Common Share will also include a warrant to purchase a Common Share (a “Warrant Share”) at a price of $1.71 per Warrant Share. Gross proceeds from the Public Offering, before deducting underwriting discounts and commissions and offering expenses payable by Aptose, are expected to be approximately US $8.4 million. The underwriters have been granted a 30-day option to purchase up to an additional 736,842 Common Shares and/or 736,842 Warrants in the Public Offering, under the same terms and conditions.]]>https://www.globenewswire.com/news-release/2023/12/09/2793449/0/en/Aptose-Tuspetinib-Clinical-Data-Featured-in-Oral-Presentation-at-the-2023-ASH-Annual-Meeting.html?f=22&fvtc=4&fvtv=26345Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting2023-12-09T23:30:00Z<![CDATA[SAN DIEGO and TORONTO, Dec. 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that a growing body of clinical data for Aptose’s lead compound tuspetinib (TUS), demonstrates significant benefit as a single agent and in combination with venetoclax (VEN) in patients with relapsed or refractory acute myeloid leukemia (R/R AML) in the ongoing APTIVATE Phase 1/2 study. Data were presented in an oral presentation today at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition by lead investigator Naval G. Daver, M.D., Professor, Director Leukemia Research Alliance Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.]]>https://www.globenewswire.com/news-release/2023/11/30/2789005/0/en/Aptose-Appoints-Fletcher-Payne-Chief-Business-Officer-Expanding-his-Executive-Role.html?f=22&fvtc=4&fvtv=26345Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role2023-11-30T21:59:54Z<![CDATA[SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the appointment of Fletcher Payne to Chief Business Officer, in addition to his role as Senior Vice President, Chief Financial Officer.]]>https://www.globenewswire.com/news-release/2023/11/09/2777755/0/en/Aptose-Reports-Results-for-the-Third-Quarter-2023.html?f=22&fvtc=4&fvtv=26345Aptose Reports Results for the Third Quarter 20232023-11-09T21:00:00Z<![CDATA[SAN DIEGO and TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months and nine months ended September 30, 2023, and provided a corporate update.]]>https://www.globenewswire.com/news-release/2023/11/02/2772405/0/en/Aptose-Tuspetinib-Clinical-Data-Selected-for-Oral-Presentation-at-the-2023-ASH-Annual-Meeting.html?f=22&fvtc=4&fvtv=26345Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting2023-11-02T13:00:00Z<![CDATA[Data from the Ongoing APTIVATE International Phase 1/2 Study in Relapsed/Refractory AML Patients Data from the Ongoing APTIVATE International Phase 1/2 Study in Relapsed/Refractory AML Patients]]>https://www.globenewswire.com/news-release/2023/10/30/2769327/0/en/Aptose-Presents-Highlights-from-Clinical-Update-Webcast-Featuring-Latest-Available-Data-on-AML-Drug-Tuspetinib.html?f=22&fvtc=4&fvtv=26345Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib2023-10-30T13:15:00Z<![CDATA[SAN DIEGO and TORONTO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, released highlights from a clinical update event held today, October 30, 2023, in conjunction with the European School of Haematology (ESH) 6th International Conference: Acute Myeloid Leukemia “Molecular and Translational”: Advances in Biology and Treatment, being held in Estoril, Portugal (the “ESH 2023 Conference”).]]>https://www.globenewswire.com/news-release/2023/10/26/2767370/0/en/Aptose-to-Report-Third-Quarter-2023-Financial-Results-and-Hold-Conference-Call-on-Thursday-November-9-2023.html?f=22&fvtc=4&fvtv=26345Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 20232023-10-26T11:11:00Z<![CDATA[SAN DIEGO and TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, after the close of the market, and provide a corporate update.]]>